Welcome to our dedicated page for Bioxcel Therapeutics news (Ticker: BTAI), a resource for investors and traders seeking the latest updates and insights on Bioxcel Therapeutics stock.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company that uses artificial intelligence, big data, and proprietary machine learning algorithms to develop medicines in neuroscience. News about BioXcel Therapeutics often centers on its commercial product IGALMI (dexmedetomidine) sublingual film and its investigational program BXCL501 for the acute treatment of agitation associated with schizophrenia, bipolar disorders, and Alzheimer’s dementia.
Investors and clinicians following BTAI news can expect updates on late‑stage clinical programs such as the SERENITY At‑Home Pivotal Phase 3 trial, which evaluated the safety of a 120 mcg dose of BXCL501 for at‑home treatment of agitation in bipolar disorders or schizophrenia, and the TRANQUILITY In‑Care Phase 3 trial, designed to study agitation associated with Alzheimer’s dementia in care facilities. Company announcements have highlighted that SERENITY At‑Home met its primary safety endpoint and reported exploratory efficacy findings related to repeated dosing and symptom resolution across thousands of agitation episodes.
BioXcel Therapeutics’ news flow also includes regulatory and development milestones, such as plans to submit a supplemental New Drug Application (sNDA) seeking FDA approval for IGALMI use in the at‑home setting, positive correlation study results supporting the use of the modified CGI‑S scale, and presentations of clinical data at medical conferences. Corporate updates, including financing activities under an at‑the‑market equity program, Nasdaq listing compliance notices, and leadership or governance developments, are typically disclosed through SEC filings and press releases.
This news page aggregates these company‑specific developments so readers can review BioXcel Therapeutics’ clinical, regulatory, and corporate announcements over time. For those tracking BTAI, it provides a focused view of how the IGALMI and BXCL501 programs, as well as the broader pipeline through OnkosXcel Therapeutics in immuno‑oncology, progress through research, regulatory review, and commercialization efforts.
BioXcel Therapeutics, Inc. (BTAI) announced that Dr. Vimal Mehta, the Founder and CEO, will present at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 3:30 PM ET. The event will showcase the company's innovative use of artificial intelligence in developing therapies aimed at neuroscience and immuno-oncology. A live webcast of the presentation will be available on the company's website, with an archive accessible for 30 days post-event. BioXcel is known for its drug re-innovation approach, focusing on advanced clinical programs like BXCL501 and BXCL701.
BioXcel Therapeutics (BTAI) announced a conference call scheduled for May 12, 2020, at 8:30 AM ET, to discuss its Q1 2020 operating and financial results. The call will provide insights into the company’s performance in the clinical-stage biopharmaceutical sector, focusing on AI-driven therapy development in neuroscience and immuno-oncology. The company is known for its advanced programs, including BXCL501 for neuropsychiatric agitation and BXCL701 for rare prostate cancer and pancreatic cancer treatments.